Carl Atkinson*, Yongquan Gong, Yuxiang Huang, Emily Pauling, Martin Goddard, Stephen Tomlinson
Oct. 1, 2008, Posters - 10:30 a.m. - noon, Session 2, Poster 196
Treatment with a highly inhibitory monoclonal antibody directed to the C3d ligand binding site on human CR2/CD21 suppresses antigen-specific immune responses in vivo
Liudmila Kulik*, Jonathan P. Hannan, Brigitte T. Huber, V. Michael Holers
Oct. 1, 2008, Animal models (Room: Montreal), 9:30 a.m. - 9:45 a.m., Oral 49
About Taligen Therapeutics
Taligen Therapeutics is focused on the discovery and development of novel protein therapeutics that are designed to modulate the alternative pathway of the complement system to treat a wide range of inflammatory conditions and diseases. The company's lead therapeutic candidates are monoclonal antibodies and recombinant fusion proteins that target key factors in the alternative pathway, which Taligen's founders have validated as an important amplification loop in the inflammation process. Taligen's headquarters and late-stage research and development operations are located in Cambridge, Mass. The company also maintains a drug discovery operation in Denver under Taligen's chief scientific officer Michael Holers, M.D., which closely collaborates with an international complement biology research community. For more information, visit http://www.taligentherapeutics.com.
This press release contains forward-looking statements that involve
risks and uncertainties, including statements relating to development of
the Company's product candidates and potential advantages of the Company's
technology and product candidates. Actual results could differ materially
from those projected and the Compan
|SOURCE Taligen Therapeutics Inc.|
Copyright©2008 PR Newswire.
All rights reserved